Sutro Biopharma (STRO) – Research Analysts’ Recent Ratings Changes

Sutro Biopharma (NASDAQ: STRO) has recently received a number of price target changes and ratings updates:

• 5/23/2026 – Sutro Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/15/2026 – Sutro Biopharma was given a new $43.00 price target by Leerink Partners. They now have an “outperform” rating on the stock.
• 5/15/2026 – Sutro Biopharma had its price target raised by HC Wainwright from $28.00 to $50.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Sutro Biopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 5/4/2026 – Sutro Biopharma was upgraded by Truist Financial Corporation to “strong-buy”.
• 5/1/2026 – Sutro Biopharma was upgraded by Lifesci Capital to “strong-buy”.
• 4/30/2026 – Sutro Biopharma was given a new $50.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 4/30/2026 – Sutro Biopharma was upgraded by Mizuho to “strong-buy”. They now have a $50.00 price target on the stock.
• 4/23/2026 – Sutro Biopharma had its price target raised by Citizens Jmp from $35.00 to $41.00. They now have a “market outperform” rating on the stock.
• 4/17/2026 – Sutro Biopharma had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/17/2026 – Sutro Biopharma had its price target raised by Citizens Jmp from $23.00 to $35.00. They now have a “market outperform” rating on the stock.
• 4/7/2026 – Sutro Biopharma is now covered by Leerink Partners. They set an “outperform” rating and a $38.00 price target on the stock.

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.